JanCBucknerMD

PubMed

• 12 citations
  Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
  Evanthia Galanis, Katharine E Dooley, S Keith Anderson, Cheyne B Kurokawa, Xiomara W Carrero
  Nature Communications. 2024-01-12
• 34 citations
  Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Al...
  Joshua D Palmer, Brett G Klamer, Karla V Ballman, Paul D Brown, Jane H Cerhan
  JAMA Oncology. 2022-12-01
• 3 citations
  A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology.
  Rahma Warsame, Joselle Cook, Briant Fruth, Joleen Hubbard, Katrina Croghan
  Contemporary Clinical Trials Communications. 2022-10-01

Journal Articles

• Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma Reponse to Rosenow F, et al  
  Jaeckle KA, Ballman K, Furth A, Buckner JC, Neuro Oncol, 1/1/2010
• Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma Response to Rossetti AO, et al  
  Jaeckle KA, Ballman K, Furth A, Buckner JC, Neurology, 1/1/2010
• CNS malignancies: At last, real progress  
  Lawrence TS, Buckner JC, Lang FF, J Clin Oncol, 1/10/2006
• Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study  
  Brown PD, Petersen IA, Schomberg PJ, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, Buckner JC, Shaw EG, Arusell R, Int J Radiat Oncol Biol Phys, 1/1/2005
• Prospective study of quality of life in adults with newly diagnosed high-grade glioma: A North Central Cancer Treatment Group trial  
  Brown P, Ballman K, Rummans T, Maurer M, Sloan J, Boeve B, Gupta L, Tang-Wai D, Arusell R, Clark M, Buckner J, J Neuro-Oncol, 1/1/2005
• Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: Randomized comparison of stereotactic radiosurgery followed by conventional...  
  Souhami L, Podgorsak EB, Mehta MP, Brachman D, Werner-Wasik M, Curran WJ, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Int J Radiat Oncol Biol Phys, 1/1/2005
• In regard to Dr Souhami et al-In reply to Dr Kondziolka et al  
  Souhami L, Podgorsak EB, Mehta MP, Brachman D, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Int J Radiat Oncol Biol Phys, 1/1/2005
• Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination (Response to letter to editor)  
  Brown P, Buckner J, J Clin Oncol, 1/1/2004
• Brain Tumors  
  Buckner JC (Guest Editor), Sem Oncol, 1/1/2004
• Efficacy of antineoplastons A10 and AS2-1-reply  
  Buckner JC, Reid J, Malkin M, Mayo Clin Proc, 1/1/1999
• Training resource document for curriculum development in medical oncology  
  Mortimer JE, Bajorin D, Buckner J, Leichman CG, Mayer R, Press OW, Journal of Clinical Oncology, 1/1/1998
• The role of chemotherapy in the treatment of patients with brain metastases from solid tumors  
  Buckner JC, Cancer and Metastasis Reviews, 1/1/1991
• Join now to see all

Books/Book Chapters

• Brain Tumors 
  Chapter: Esthesioneuroblastoma: management and outcome. 
  Page 767 - 778Fogelson JL, Link MJ, Olsen KD, Moore EJ, Giannini C, Foote RL, Buckner JC2012
• Primary Central Nervous System Tumors Pathogenesis and Therapy 
  Chapter: Complications of Therapy. 
  Page 103 - 141Johnson D, Ashman J, Brown P, Lachance DH, Buckner JCEditors: Nordan A, Reardon D, Wen P.Humana Press, New York, NY2010
• DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology 
  Chapter: Neoplasms of the central nervous system. 
  Page 1975 - 2032Mehta MP, Buckner J, Sawaya RP, Cannon GMEditors: DeVita VT Jr. Lawrence TS, Rosenberg SA.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 8th,2008
• Brain tumors: practical guide to diagnosis and treatment. Volume 89 (Neurological Disease and Therapy) 
  Chapter: Oligodendroglioma and mixed tumors. 
  Page 193 - 206Rao RD, Buckner JC, Jenkins REditors: Baehring JM, Piepmeier JM.Informa Healthcare, New York2007
• Medical Oncology Self-Evaluation Program (American Society of Clinical Oncology-SEP) 
  Chapter: Central nervous system tumors. 
  Page 291 - 309Buckner JCEditors: Moore A.American Society of Clinical Oncology, Alexadria, VAEdition 4th,2007
• Neurological therapeutics: principles and practice 
  Chapter: Diffuse cerebral gliomas in adults. 
  Page 832 - 853Galanis E, Buckner JCEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
• Oncology: an evidence-based approach 
  Chapter: Central nervous system tumors. 
  Page 487 - 505Rao RD, Brown PD, Giannini C, Maher CO, Meyer FB, Galanis E, Erickson BJ, Buckner JCEditors: Chang AE, et al.Springer, New York2006
• Cancer of the nervous system 
  Chapter: Chemotherapy for central nervous system tumors. 
  Page 193 - 208Rao RD, Buckner JCEditors: Black PM, Loeffler JS.Lippincott Williams & Wilkins, PhiladelphiaEdition 2nd,2005
• Principles of neuro-oncology 
  Chapter: Clinical trial design in neuro-oncology. 
  Page 217 - 232O'Fallon JR, Buckner JCEditors: Schiff D, O'Neill BP.McGraw-Hill Medical Pub. Division, New York2005
• Principles of Neuro-Oncology 
  Chapter: Clinical trials methodology/issues. 
  Page 217 - 232O'Fallon JR, Buckner JCEditors: Schiff D, O'Neill BP.McGraw Hill, New York2005
• American Society of Clinical Oncology Educational Book 
  Chapter: Current Treatment of Anaplastic Astrocytoma: Multiple Unanswered Questions. 
  Page 175 - 179Buckner JCEditors: Perry MC.American Society of Clinical Oncology, Alexadria, VA2005
• Oncology Medical Knowledge Self-Assessment Program (MKSAP) 
  Chapter: Central nervous system tumors. 
  Page 341 - 361Buckner JCEditors: Cheson BD.American Society of Clinical Oncology, Alexadria, VAEdition 3rd,2004
• Neurological therapeutics : principles and practice 
  Chapter: Diffuse cerebral gliomas in adults. 
  Page 737 - 753Galanis E, Buckner JCEditors: Noseworthy JH.Martin Dunitz, London2003
• Tumors: An Encyclopedic Approach 
  Chapter: Esthesioneuroblastoma-management and outcome. 
  Page 899 - 912Link MJ, Ebersold MJ, Olsen KD, Foote RL, Buckner JC, Quast LMEditors: Kaye AH, Laws Jr. ER.Churchill Livingstone, LondonEdition 2nd,2001
• Clinical Radiation Oncology 
  Chapter: High-grade gliomas. 
  Page 355 - 378Algan O, Nelson DF, Dinapoli RP, Galanis E, Raffel C, Parisi JE, Buckner JC, Jenkins RBEditors: Gunderson LL, Tepper JE.Churchill Livingstone, New York2000
• Neuro-Oncology: The Essentials 
  Chapter: Intra-arterial chemotherapy. 
  Page 234 - 239Buckner JCEditors: Bernstein M, Berger MS.Thieme Medical Publishers, Inc., New York2000
• The Gliomas 
  Chapter: Systemic sequelae of chemotherapy for gliomas. 
  Page 759 - 767Buckner JCEditors: Berger MS, Wilson CB.W. B. Saunders Company, Philadelphia1999
• Brain Tumor Research and Therapy 
  Chapter: Clinical trials with interferon-alpha as a chemosensitizer in gliomas. 
  Page 339 - 347Buckner JCEditors: M. Nagai.Springer-Verlag, Tokyo1996
• Brain Tumors: An Encyclopedic Approach 
  Chapter: Esthesioneuroblastoma. 
  Page 825 - 838Ebersold MJ, Olsen KD, Foote RL, Buckner JC, Quast LMEditors: Kaye AH, Laws Jr. ER.Churchill Livingstone, Edinburgh1995
• Cancer 
  Chapter: Treatment of metastatic cancer to the brain. 
  Page 2170 - 2186Wright DC, Delaney TF, Buckner JCEditors: DeVita Jr. VT, Hellman S, Rosenberg SA.J. B. Lippincott Co., PhiladelphiaEdition 4th,1993
• Join now to see all

Abstracts/Posters

• RTOG 9802: Phase III Study of Radiation Therapy (RT) with or without Procarbazine, CCNU, and Vincristine (PCV) in Low-Grade Glioma.
  Jan C. Buckner, MD, NRG Oncology Semi-Annual Meeting, Chicago, IL, 1/11/2014
• RTOG 9802: Phase III Study of Radiation Therapy (RT) with or without Procarbazine, CCNU, and Vincristine (PCV) in Low-Grade Glioma.
  Jan C. Buckner, MD, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 1/1/2014
• Standardizing measurement of tobacco use in cancer clinical trials.
  Land SR, Toll B, Warren GW, Brandon TH, Mitchell SA, Dresler CM, Gritz ER, Schnoll R, Sarna L, Moinpour C, Ostroff JS, Khuri FR, Buckner JC, Cummings KM, Herbst RS, Sh..., J Clin Oncol, 1/1/2014
• Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.
  Singh JA, Locke DE, Satele D, Puttabasavaiah S, Buckner JC, Sloan JA, J Clin Oncol, 1/1/2014
• An update on high-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
  Wilcox RE, Litzow MR, Galanis E, Gill P, Buckner JC, J Clin Oncol, 1/1/2014
• Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
  Buckner JC, Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary J-P, Fisher BJ, Kim H, Mur..., J Clin Oncol, 1/1/2014
• Impact of adjuvant temozolmide and IDH mutation status among patients with anaplastic astrocytoma.
  Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Laack NN, Parney IF, Uhm JH, Buckner JC, Am Soc Clin Oncol, 1/1/2013
• NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and ...
  Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Giannini C, Erickson BJ, Buckner JC, J Clin Oncol, 1/1/2013
• Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final res...
  Galanis E, Sarkaria JN, Anderson SK, Wu W, Jaeckle KA, Giannini C, Buckner JC, Wen PY, Alliance for Clinical Trials in Oncology, J Clin Oncol, 1/1/2013
• Recurrence patterns in anaplastic astrocytoma: a retrospective study of patients treated at the Mayo Clinic.
  Hardie J, Laack N, Kizilbash S, Buckner J, Giannini C, Uhm J, Parney I, Jenkins R, Decker P, Voss J, Neuro Oncol, 1/1/2013
• Factors contributing to survival in patients with anaplastic astrocytoma: a retrospective study of patients treated at a single institution.
  Hardie JG, Kizilbash S, Buckner J, Pulley I, Giannini C, Uhm J, Laack N, Int J Radiat Oncol Biol Phys, 1/1/2013
• Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemo-radiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final res...
  Laack NN, Galanis E, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Jaeckle KA, Sarkaria JN, J Clin Oncol, 1/20/2012
• Relationship between overall survival and progression-free survival for recent NCCTG Glioblastoma Multiforme trials.
  Wu W, Galanis E, Buckner J, Jaeckle K, Sargent D, J Clin Oncol, 1/1/2012
• Chemotherapy plus radiotherapy (CT-RT) vs. RT alone for patients with anaplastic oligodendroglioma: long term results of the RTOG 9402 phase III study.
  Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW, Brachman D, Buckner JC, Fink KL, Souhami L, Laperriere N, Curra WJ, Mehta MP, J Clin Oncol, 1/1/2012
• NCCTG N057K phase II trial of everolimus, temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: a north central cancer treatment group trial.
  Ma D, Galanis E, Schiff D, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Buckner JC, Sarkaria JN, J Clin Oncol, 1/1/2012
• Utility of Circulating Biomarkers As Outcome Predictors in Metastatic Colorectal Cancer and Recurrent Glioblastoma Multiforme Patients Treated with Bevacizumab/Sorafenib.
  Lafky JM, Anderson SK, Morlan BW, Nelson GD, Carrero XW, Kumar S, Reynolds JT, Stella PJ, Dakhil SR, Loui WS, Alberts SR, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, G..., Proc Am Assoc Cancer Res, 1/1/2012
• Five decades of adult low-grade gliomas: patterns of care over time.
  Youland R, Brown PD, Buckner JC, Parney IF, Uhm JH, Laack NN, Int J Radiat Oncol Biol Phys, 1/1/2012
• NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.
  Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Scheithauer BW, Erickson BJ, Buckner JC, J Clin Oncol, 1/1/2011
• A longitudinal study of alterations in cognitive function and brain metabolites among women receiving chemotherapy for primary breast cancer.
  Kohli S, Buckner JC, Cerhan JH, Kantarci K, Barton DL, Sloan JA, Novotny PJ, J Clin Oncol, 1/1/2011
• Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with beva...
  Anderson SK, Lafky JM, Carrero XW, Kimlinger TK, Halling TM, Kumar S, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, J Clin Oncol, 1/1/2011
• FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K.
  Sarkaria J, Peller P, Galanis E, Jacobson M, Wu W, Jaeckle K, Buckner J, J Clin Oncol, 1/1/2011
• Optimal radiotherapy target volumes in intracranial non-germinomatous germ cell tumors: long-term institutional experience with chemotherapy, surgery, and dose-and fie...
  Laack N, Blanchard M, Buckner J, Neuro-oncol, 1/1/2011
• Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coef...
  Kaufmann TJ, Anderson SK, Jaeckle KA, Uhm JH, Northfelt DW, Flynn PJ, Buckner JC, Galanis E, Neuro-oncol, 1/1/2011
• Inherited variants impact survival in uniformly treated glioblastoma patients.
  Xiao YY, Decker PA, Rice T, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, O'Neill BP, Buckner JC, Burch PA, Thomps..., Neuro-oncol, 1/1/2011
• NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).
  Galanis E, Anderson SK, Lafky JM, Kaufmann TJ, Uhm JH, Giannini C, Kumar SK, Northfelt DW, Flynn PJ, Jaeckle KA, Buckner JC, Neuro-oncol, 1/1/2011
• Join now to see all

Lectures

• To Chemo or Not to Chemo: The Question for High-Risk, Low-Grade Gliomas 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• "Update in Neuro-Oncology" 
  Minneapolis, MN - 1/26/2014
• Update on management of oligodendroglioma. 
  Sydney, Australia - 1/25/2013
• The Role of Angiogenesis Inhibitors in Clinical Neuro-Oncology. 
  Sydney, Australia - 1/25/2013
• Update on management of grade II and III glioma. 
  Sydney, Australia - 1/25/2013
• Application of antiangiogenic agents to clinical practice. 
  San Francisco, CA - 1/22/2013
• Cooperative Groups to NCTN; CCOP to NCORP: A Group Chair Perspective. 
  Shady Grove, MD - 1/20/2013
• The Prognostic and Predictive Significance of Molecular Markers in Grade 2 and Grade 3 Gliomas. 
  Beijing, China - 1/20/2013
• The role of molecular markers in guiding therapy for oligodendroglioma. 
  Tianjin, China - 1/1/2013
• Grand Rounds: "What's New in Neuro-Oncology?" 
  NorthShore University Hospital, Chicago, IL - 1/1/2013
• Update in Neuro-Oncology. 
  Columbus, OH - 1/20/2012
• The Role of Angiogenesis Inhibitors in Central Nervous System Tumors. 
  Minneapolis, MN - 1/19/2012
• Angiogenesis Inhibitors in Brain Tumors: Promise and Pitfalls. 
  Minneapolis, MN - 1/18/2012
• What's New in Neuro-Oncology? 
  Chicago, IL - 1/8/2012
• How do we Interpret Quality of Life Data in Neuro-Oncology Clinical Trials? 
  Marseilles, France - 1/6/2012
• ABTA-Mayo Clinic Partnership. 
  Lincolnshire, IL - 1/29/2011
• Cooperative Group Chairs Report: Response to the IOM Report. 
  Washington, DC - 1/21/2011
• Clinical Case Management in Neuro-Oncology. 
  1/4/2011
• "Difficult Decisions and Dilemmas in Oncology Case Management" 
  1/7/2010
• "NCCTG/MCCRC Clinical Trials" 
  Anchorage, AK - 1/3/2010
• Keynote Speaker: "Humor to Fight the Tumor." 
  Minneapolis, MN - 1/1/2010
• Newly Diagnosed Glioblastoma: Shift in Survival? 
  Orlando, FL - 1/31/2009
• The Emerging Role of VEGF Pathway Inhibitors in Glioma Therapy: More Questions than Answers? (Visiting Professor) 
  Cleveland Clinic, Cleveland, OH - 1/10/2009
• Recurrent Gliomas: Practical Assessment of Progression and Efficacy. 
  Bologna, Italy - 1/22/2008
• The Lean Experiment: Mayo Clinic and North Central Cancer Treatment Group. 
  Bethesda, MD - 1/18/2008
• Join now to see all

Other

• Classification and regression tree (CART) models of time to progression and overall survival in patients with recurrent glioma. 
  Buckner JC, Novotny P, Schaefer P, O'Fallon JR
  1/1/2001
• Safety of thrice daily hyperfractionated radiation and BCNU for high grade glioma. 
  Rao RD, Thome S, O'Fallon JR, Earle JD, Dinapoli RP, Buckner JC
  1/1/2001
• Technology assessment report: blood brain barrier disruption chemotherapy. 
  Moynihan T, Buckner JC, Hall W, Wilkowske M, Institute for Clinical Systems Integration
  1/1/1998